Clinical trial
Bevacizumab in Advanced Hepatocellular Carcinoma
NCT00162669 · Gustave Roussy, Cancer Campus, Grand Paris, Other · Unknown status
Key facts
| NCT number | NCT00162669 |
|---|---|
| Title | Bevacizumab in Advanced Hepatocellular Carcinoma |
| Official title | Phase II Study Evaluating the Efficacy of Bevacizumab (Avastin@) in Hepatocellular Carcinoma Not Amenable to Curative Treatment |
| Lead sponsor | Gustave Roussy, Cancer Campus, Grand Paris, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | bevacizumab |
| Enrollment | 50 |
| Start date | May 1, 2005 |
| First posted | Sep 13, 2005 |
| Last update posted | Sep 8, 2006 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: